JP2012522030A - ヘスペレチンの生体利用率を増大させるためのフラボノイドの使用 - Google Patents

ヘスペレチンの生体利用率を増大させるためのフラボノイドの使用 Download PDF

Info

Publication number
JP2012522030A
JP2012522030A JP2012502640A JP2012502640A JP2012522030A JP 2012522030 A JP2012522030 A JP 2012522030A JP 2012502640 A JP2012502640 A JP 2012502640A JP 2012502640 A JP2012502640 A JP 2012502640A JP 2012522030 A JP2012522030 A JP 2012522030A
Authority
JP
Japan
Prior art keywords
hesperetin
use according
compound
flavonoid compound
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012502640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522030A5 (enExample
Inventor
ウォルター ブラント，
ゲイリー ウィリアムソン，
ブラデレン， ペーター ファン
イヴォンヌ エム． シー． エム． リートジェンス，
Original Assignee
ネステク ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40908614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012522030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ネステク ソシエテ アノニム filed Critical ネステク ソシエテ アノニム
Publication of JP2012522030A publication Critical patent/JP2012522030A/ja
Publication of JP2012522030A5 publication Critical patent/JP2012522030A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Fodder In General (AREA)
JP2012502640A 2009-03-31 2010-03-30 ヘスペレチンの生体利用率を増大させるためのフラボノイドの使用 Pending JP2012522030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09156910.3 2009-03-31
EP09156910A EP2241313A1 (en) 2009-03-31 2009-03-31 Use of flavonoids to increase the bioavailability of hesperetin
PCT/EP2010/054215 WO2010112510A1 (en) 2009-03-31 2010-03-30 Use of flavonoids to increase the bioavailability of hesperetin

Publications (2)

Publication Number Publication Date
JP2012522030A true JP2012522030A (ja) 2012-09-20
JP2012522030A5 JP2012522030A5 (enExample) 2013-05-09

Family

ID=40908614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502640A Pending JP2012522030A (ja) 2009-03-31 2010-03-30 ヘスペレチンの生体利用率を増大させるためのフラボノイドの使用

Country Status (11)

Country Link
US (1) US8685935B2 (enExample)
EP (2) EP2241313A1 (enExample)
JP (1) JP2012522030A (enExample)
CN (1) CN102448455A (enExample)
AR (1) AR076040A1 (enExample)
AU (1) AU2010230211A1 (enExample)
BR (1) BRPI1014083A2 (enExample)
CL (1) CL2011002451A1 (enExample)
MX (1) MX2011010376A (enExample)
SG (1) SG174609A1 (enExample)
WO (1) WO2010112510A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016216440A (ja) * 2015-05-14 2016-12-22 花王株式会社 カテキン類吸収促進剤
JP2019515022A (ja) * 2016-05-16 2019-06-06 グローバル バイオライフ インコーポレーテッドＧｌｏｂａｌ Ｂｉｏｌｉｆｅ Ｉｎｃ． 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物
JP2019151568A (ja) * 2018-03-01 2019-09-12 アサヒ飲料株式会社 酸性スフィンゴミエリナーゼ活性向上剤、酸性スフィンゴミエリナーゼ活性向上用組成物、及び抗アレルギー用組成物
WO2020153710A3 (ko) * 2019-01-22 2020-10-15 조선대학교 산학협력단 헤스페레틴을 포함하는 피부과민반응을 조절하기 위한 조성물
KR20230095911A (ko) * 2021-11-16 2023-06-29 가부시키가이샤 다이토 기켄 커피머신
JP2024525957A (ja) * 2021-08-20 2024-07-12 中国農業科学院鄭州果樹研究所 ヘスペレチン含有組成物およびその血糖降下における相乗的応用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234310A1 (en) * 2009-03-11 2010-09-16 Bionovo, Inc. Estrogenic compounds and their methods of use
CN103462957A (zh) * 2012-06-07 2013-12-25 上海中医药大学 一种异鼠李素的新用途
CN102697768A (zh) * 2012-06-07 2012-10-03 中国人民解放军第二军医大学 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途
US9053152B2 (en) 2012-08-06 2015-06-09 Sap Portals Israel Ltd Search and context based creation in dynamic workspaces
CN102861090A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid C在治疗胆管癌药物中的应用
CN102861060A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid B在治疗白血病药物中的应用
CN102861048A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid A在治疗鼻咽癌药物中的应用
CN102861050A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid A在治疗胰腺癌药物中的应用
CN102861075A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid B在治疗胃癌药物中的应用
CN102861081A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid C在治疗皮肤癌药物中的应用
CN102861046A (zh) * 2012-10-27 2013-01-09 南京大学 Houttuynoid A在治疗卵巢癌药物中的应用
CN102861053B (zh) * 2012-10-27 2013-07-10 南京大学 Houttuynoid D在治疗白血病药物中的应用
CN102861086A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid E在治疗卵巢癌药物中的应用
CN102861092A (zh) * 2012-10-27 2013-01-09 吴俊华 Houttuynoid C在治疗肺癌药物中的应用
US10722584B2 (en) 2012-11-29 2020-07-28 Societe Des Produits Nestle S.A. Increasing the bioavailability of flavan-3-ols by polyphenols
GB201407694D0 (en) * 2014-05-01 2014-06-18 Univ Montfort Compound
WO2016128503A1 (en) * 2015-02-11 2016-08-18 Bioactor Bv Compounds and compositions for improving power output and oxygen efficiency
US12257231B2 (en) * 2015-02-13 2025-03-25 Global Biolife Inc. Method and composition for preventing and treating viral infections
US10383842B2 (en) * 2015-02-13 2019-08-20 Global Biolife Inc. Method and composition for preventing and treating viral infections
CN105167193B (zh) * 2015-06-17 2019-02-19 湖北中烟工业有限责任公司 含黄酮香精的烟用嘴棒及其制备方法
CN104983728B (zh) * 2015-08-07 2018-01-05 上海中医药大学 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用
KR101725461B1 (ko) * 2015-12-29 2017-04-10 연세대학교 산학협력단 디오스민을 유효성분으로 포함하는 탈모 예방 또는 치료용, 또는 발모 또는 육모 촉진용 조성물
US20220249530A1 (en) * 2017-08-28 2022-08-11 Global Biolife Inc. Method and composition for preventing and treating viral infections
US11311563B2 (en) * 2017-08-28 2022-04-26 Global Biolife Inc. Method and composition for preventing and treating viral infections
KR20210021827A (ko) 2019-08-19 2021-03-02 연세대학교 산학협력단 켐페라이드를 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물
CN111281866B (zh) * 2020-03-30 2021-09-28 中国药科大学 一种预防或治疗溃疡性结肠炎的中药化学制剂
CN112569246A (zh) * 2020-12-22 2021-03-30 成都大学 用于抗炎镇痛止血的药物及药物活性组分筛选方法
CN114948977B (zh) * 2021-02-25 2023-11-28 南京中医药大学 二氢黄酮苷衍生物在制备防治结肠炎的药物中的用途
CN113679733A (zh) * 2021-08-31 2021-11-23 广东金骏康生物技术有限公司 一种抑制结肠炎的化合物及其应用
CN117224530A (zh) * 2023-09-15 2023-12-15 北京东方百奥医药开发有限公司 一种改善雄性哺乳动物睾酮水平的化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003073279A (ja) * 2001-08-31 2003-03-12 Toyo Seito Kk 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
JP2009209066A (ja) * 2008-03-03 2009-09-17 Toyo Seito Kk 生体吸収性に優れたヘスペレチン組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6666594A (en) 1993-04-20 1994-11-08 Procter & Gamble Company, The Methods of using hesperetin for sebum control and treatment of acne
JPH08283154A (ja) * 1995-04-12 1996-10-29 Nippon Shinyaku Co Ltd 脂質代謝改善剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003073279A (ja) * 2001-08-31 2003-03-12 Toyo Seito Kk 即効性および持続性を有するフラボノイド配糖体を含有する経口栄養補給剤
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
JP2009209066A (ja) * 2008-03-03 2009-09-17 Toyo Seito Kk 生体吸収性に優れたヘスペレチン組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015008869; Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．２１，　Ｎｏ．７　（２００４）, １２６３-１２７３ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016216440A (ja) * 2015-05-14 2016-12-22 花王株式会社 カテキン類吸収促進剤
JP2019515022A (ja) * 2016-05-16 2019-06-06 グローバル バイオライフ インコーポレーテッドＧｌｏｂａｌ Ｂｉｏｌｉｆｅ Ｉｎｃ． 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物
JP2022058792A (ja) * 2016-05-16 2022-04-12 グローバル バイオライフ インコーポレーテッド 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物
JP7376624B2 (ja) 2016-05-16 2023-11-08 グローバル バイオライフ インコーポレーテッド 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物
JP2019151568A (ja) * 2018-03-01 2019-09-12 アサヒ飲料株式会社 酸性スフィンゴミエリナーゼ活性向上剤、酸性スフィンゴミエリナーゼ活性向上用組成物、及び抗アレルギー用組成物
WO2020153710A3 (ko) * 2019-01-22 2020-10-15 조선대학교 산학협력단 헤스페레틴을 포함하는 피부과민반응을 조절하기 위한 조성물
JP2024525957A (ja) * 2021-08-20 2024-07-12 中国農業科学院鄭州果樹研究所 ヘスペレチン含有組成物およびその血糖降下における相乗的応用
JP7588274B2 (ja) 2021-08-20 2024-11-21 中国農業科学院鄭州果樹研究所 ヘスペレチン含有組成物およびその血糖降下における相乗的応用
KR20230095911A (ko) * 2021-11-16 2023-06-29 가부시키가이샤 다이토 기켄 커피머신
KR102566640B1 (ko) 2021-11-16 2023-08-11 가부시키가이샤 다이토 기켄 커피머신

Also Published As

Publication number Publication date
SG174609A1 (en) 2011-10-28
EP2413928A1 (en) 2012-02-08
EP2241313A1 (en) 2010-10-20
WO2010112510A1 (en) 2010-10-07
BRPI1014083A2 (pt) 2016-04-19
US20120022010A1 (en) 2012-01-26
AR076040A1 (es) 2011-05-11
CN102448455A (zh) 2012-05-09
CL2011002451A1 (es) 2012-04-20
MX2011010376A (es) 2011-10-12
US8685935B2 (en) 2014-04-01
AU2010230211A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
US8685935B2 (en) Use of flavonoids to increase the bioavailability of hesperetin
Alexander et al. Role of herbal bioactives as a potential bioavailability enhancer for active pharmaceutical ingredients
Salehi et al. Hesperetin’s health potential: Moving from preclinical to clinical evidence and bioavailability issues, to upcoming strategies to overcome current limitations
US9211298B2 (en) Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
CA2999763C (en) Flavonoid compositions and methods of use
EP2040708B1 (en) Quercetin-containing compositions
ES2863561T3 (es) Fitocomplejos de Citrus bergamia
EP2859896B1 (en) Pharmaceutical compositions for the treatment of muscular disorders
Roy et al. Anti-inflammatory effects of different dietary antioxidants
Lee Challenges in providing credible scientific evidence of health benefits of dietary polyphenols
Pandey et al. Andrographolide: its pharmacology, natural bioavailability and current approaches to increase its content in Andrographis paniculata
AU2018203677A1 (en) Modified polyphenol compositions
KR101171832B1 (ko) 부작용을 제거한 장기간 복용 차 및 그 조성물
Minami et al. The potential of sweet orange (Citrus sinensis) in cardiovascular health: A literature review
RU2408383C1 (ru) Композиция с противоопухолевой и адаптогенной активностью (варианты) и лекарственный препарат на ее основе (варианты)
JPWO2006135084A1 (ja) 脂肪性肝炎または脂肪肝の予防または治療薬
CN102205010A (zh) 一种具有辅助降血脂功能的药物组合物
AU2015221487A1 (en) Use of flavonoids to increase the bioavailability of hesperetin
Świątek et al. Flavonoids as potential inhibitors targeting SARS-CoV-2
Cannataro et al. Polyphenols in the Mediterranean Diet: From Dietary Sources to microRNA Modulation. Antioxidants 2021, 10, 328
Ahmed et al. Role of flavonoids in obesity induced cardiovascular dysfunction
OLUWASEUN et al. SLEEP POTENTIATING EFFECT OF< I> PLEUROTUS SQUARRUSOLUS</I> ETHANOLIC EXTRACT ON DIAZEPAM-INDUCED SLEEPING TIME IN MALE WISTAR RATS
Altaf et al. Pharmacological role of bioactive compounds of date palm by-products
Shoukat Nutritional and Therapeutic Potential of Milk Thistle: A Review of Its Role in Liver Health and Beyond
Arshad et al. Bioflavonoids: sources, types, and nutraceutical maneuvers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150811